Implementation of PSA-based Active Surveillance in Prostate Cancer

References

• Papsidero LD , WojcieszynJW, HoroszewiczJS, LeongSS, MurphyGP, ChuTM. Isolation of prostatic acid phosphatase-binding immunoglobulin G from human sera and its potential for use as a tumor-localizing reagent.Cancer Res.40 (8 Pt 2), 3032 – 3035 (2008).
   Google Scholar
• Kuriyama M , WangMC, PapsideroLDet al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 40 (12), 4658 – 4662 (1980).
   PubMed Web of Science ®Google Scholar
• Ablin RJ , SoanesWA, BronsonP, WitebskyE. Precipitating antigens of the normal human prostate.J. Reprod. Fertil.22 (3), 573 – 574 (1970).
   PubMedGoogle Scholar
• Stamey TA , YangN, HayAR, McNealJE, FreihaFS, RedwineE. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.N. Engl. J. Med.317 (15), 909 – 916 (1987).
   PubMed Web of Science ®Google Scholar
• Oesterling JE , ChanDW, EpsteinJIet al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139 (4), 766 – 772 (1988).
   PubMed Web of Science ®Google Scholar
• Catalona WJ , SmithDS, RatliffTLet al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324 (17), 1156 – 1161 (1991).
   PubMed Web of Science ®Google Scholar
• Cooner WH , MosleyBR, RutherfordCL Jret al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol. 143 (6), 1146 – 1152 (1990).
   PubMed Web of Science ®Google Scholar
• Catalona WJ , RichieJP, AhmannFRet al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 151 (5), 1283 – 1290 (1994).
   PubMed Web of Science ®Google Scholar
• Siegel R , MaJ, ZouZet al. Cancer statistics, 2014. CA. Cancer J. Clin.64 (1), 9 – 29 (2014).
   PubMed Web of Science ®Google Scholar
• Etzioni R , TsodikovA, MariottoAet al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 19 (2), 175 – 181 (2008).
   PubMed Web of Science ®Google Scholar
• Etzioni R , GulatiR, TsodikovAet al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 118 (23), 5955 – 5963 (2012).
   PubMed Web of Science ®Google Scholar
• D’Amico AV , WhittingtonR, MalkowiczSBet al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (11), 969 – 974 (1998).
   PubMed Web of Science ®Google Scholar
• Schröder, FH, HugossonJ, RoobolMJet al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366 (11), 981 – 990 (2012).
   PubMed Web of Science ®Google Scholar
• Andriole GL , CrawfordED, GrubbRL3rdet al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J. Natl. Cancer Inst. 104 (2), 125 – 132 (2012).
   PubMedGoogle Scholar
• Pinsky PF , BlackaA, KramerBS, MillerA, ProrokPC, BergC. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial.Clin. Trials7 (4), 303 – 311 (2010).
   PubMed Web of Science ®Google Scholar
• Loeb S , BerglundA, StattinP. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.J. Urol.190 (5), 1742 – 1749 (2013).
   PubMed Web of Science ®Google Scholar
• Acar C , SchoffelmeerCC, TillierC, de BlokW, van MuilekomE, van der PoelHG. Quality of life in patients with low-risk prostate cancer. a comparative retrospective study: brachytherapy versus robot-assisted laparoscopic prostatectomy versus active surveillance.J. Endourol.28 (1), 117 – 124 (2013).
   PubMed Web of Science ®Google Scholar
• Sanda MG , DunnRL, MichalskiJet al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358 (12), 1250 – 1261 (2008).
   PubMed Web of Science ®Google Scholar
• Lu-Yao GL , AlbertsenPC, MooreDFet al. Outcomes of localized prostate cancer following conservative management. JAMA 302 (11), 1202 – 1209 (2009).
   PubMed Web of Science ®Google Scholar
• Klotz L . Prostate cancer overdiagnosis and overtreatment.Curr. Opin. Endocrinol. Diabetes Obes.20 (3), 204 – 209 (2013).
   PubMedGoogle Scholar
• Xia J , GulatiR, AuM, GoreJL, LinDW, EtzioniR. Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial.J. Natl Cancer. Inst.105 (8), 546 – 550 (2013).
   PubMedGoogle Scholar
• D’Amico AV . Combined-modality staging in predicting prostate-specific antigen outcome after definitive local therapy for men with clinically localized prostate cancer. In:Prostate cancer: Principles & Practice.D’AmicoAV (Ed). Lippincott Williams & Wilkins, PA, USA, 254 – 268 (2002).
   Google Scholar
• Cooperberg MR , PastaDJ, ElkinEPet al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 173 (6), 1938 – 1942 (2005).
   PubMed Web of Science ®Google Scholar
• Kattan MW , EasthamJA, StapletonAM, WheelerTM, ScardinoPT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.J. Natl Cancer Inst.90 (10), 766 – 771 (1998).
   PubMed Web of Science ®Google Scholar
• Nakanishi H , WangX, OchiaiAet al. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 110 (11), 2441 – 2447 (2007).
   PubMed Web of Science ®Google Scholar
• Bangma CH , RoobolMJ, SteyerbergEW. Predictive models in diagnosing indolent cancer.Cancer115 (13), 3100 – 3106 (2009).
   PubMed Web of Science ®Google Scholar
• Iremashvili V , Burdick-WillJ, SolowayMS. Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression.BJU Int.112 (1), 39 – 44 (2013).
   PubMed Web of Science ®Google Scholar
• Kattan MW , ZelefskyMJ, KupelianPA, ScardinoPT, FuksZ, LeibelSA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer.J. Clin. Oncol.18 (19), 3352 – 3359 (2000).
   PubMed Web of Science ®Google Scholar
• Wilt TJ , BrawerMK, JonesKMet al. Radical prostatectomy versus observation for localized prostate cancer. Prostate cancer intervention versus observation trial (PIVOT) study group. N. Engl. J. Med. 367 (3), 203 – 213 (2012).
   PubMed Web of Science ®Google Scholar
• Ganz PA , BarryJM, BurkeWet al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann. Intern. Med. 156 (8), 591 – 595 (2012).
   PubMed Web of Science ®Google Scholar
• Warlick C , TrockBJ, LandisP, EpsteinJI, CarterHB. Delayed versus immediate surgical intervention and prostate cancer outcome.J. Natl Cancer Inst.98 (5), 355 – 357 (2006).
   PubMedGoogle Scholar
• Cooperberg MR , CarrollPR, KlotzL. Active surveillance for prostate cancer: progress and promise.J. Clin. Oncol.29 (27), 3669 – 3676 (2011).
   PubMed Web of Science ®Google Scholar
• van As NJ , NormanAR, ThomasKet al. Predicting the probability of deferred radical treatment for localized prostate cancer managed by active surveillance. Eur. Urol. 54 (6), 1297 – 1305 (2008).
   PubMed Web of Science ®Google Scholar
• Tosoian JJ , TrockBJ, LandisPet al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 29 (16), 2185 – 2190 (2011).
   PubMed Web of Science ®Google Scholar
• Lees K , DurveM, ParkerC. Active surveillance in prostate cancer: patient selection and triggers for intervention.Curr. Opin. Urol.22 (3), 210 – 215 (2012).
   PubMed Web of Science ®Google Scholar
• Dall’Era MA , KonetyBR, CowanJEet al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 112 (12), 2664 – 2670 (2008).
   PubMed Web of Science ®Google Scholar
• Klotz L , ZhangL, LamA, NamR, MamedovA, LoblawA. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.J. Clin. Oncol.28 (1), 126 – 131 (2010).
   PubMed Web of Science ®Google Scholar
• Bul M , ZhuX, ValdagniR, PicklesTet al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur. Urol. 63 (4), 597 – 603 (2013).
   PubMed Web of Science ®Google Scholar
• Adamy A , YeeDS, MatsushitaKet al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J. Urol. 185 (2), 477 – 482 (2011).
   PubMed Web of Science ®Google Scholar
• Carter HB , WalshPC, LandisP, EpsteinJI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.J. Urol.167 (3), 1231 – 1234 (2002).
   PubMed Web of Science ®Google Scholar
• Venkitaraman R , NormanA, Woode-AmissahRet al. Predictors of histological disease progression in untreated, localized prostate cancer. J. Urol. 178 (3), 833 – 837 (2007).
   PubMed Web of Science ®Google Scholar
• Epstein JI , WalshPC, CarmichaelM, BrendlerCB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.JAMA271 (5), 368 – 374 (1994).
   PubMed Web of Science ®Google Scholar
• van den Bergh RC , RoemelingS, RoobolMJet al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur. Urol. 55 (1), 1 – 8 (2009).
   PubMed Web of Science ®Google Scholar
• D’Amico AV , ChenMH, RoehlKA, CatalonaWJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.N. Engl. J. Med.351 (2), 125 – 135 (2004).
   PubMed Web of Science ®Google Scholar
• Klotz L . Active surveillance for prostate cancer: for whom?J. Clin. Oncol.23 (32), 8165 – 8169 (2005).
   PubMed Web of Science ®Google Scholar
• Ng MK , Van AsN, ThomasKet al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int. 103 (7), 872 – 876 (2009).
   PubMed Web of Science ®Google Scholar
• Soloway MS , SolowayCT, WilliamsS, AyyathuraiR, KavaB, ManoharanM. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.BJU Int.101 (2), 165 – 169 (2008).
   PubMed Web of Science ®Google Scholar
• Ross AE , LoebS, LandisPet al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J. Clin. Oncol. 28 (17), 2810 – 2816 (2010).
   PubMed Web of Science ®Google Scholar
• Whitson JM , PortenSP, HiltonJFet al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J. Urol. 185 (5), 1656 – 1660 (2011).
   PubMed Web of Science ®Google Scholar
• Khatami A , AusG, DamberJE, LiljaH, LoddingP, HugossonJ. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.Int. J. Cancer120 (1), 170 – 174 (2007).
   PubMed Web of Science ®Google Scholar
• McCormack RT , RittenhouseHG, FinlayJAet al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45 (5), 729 – 744 (1995).
   PubMed Web of Science ®Google Scholar
• Woodrum DL , BrawerMK, PartinAW, CatalonaWJ, SouthwickPC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.J. Urol.159 (1), 5 – 12 (1998).
   PubMed Web of Science ®Google Scholar
• Lilja H . Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin.Urol. Clin. North. Am.20 (4), 681 – 686 (1993).
   PubMed Web of Science ®Google Scholar
• Stenman UH , HakamaM, KnektP, AromaaA, TeppoL, LeinonenJ. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.Lancet344 (8937), 1594 – 1598 (1994).
   PubMed Web of Science ®Google Scholar
• Mikolajczyk SD , MillarLS, WangTJet al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (1), 41 – 45 (2000).
   PubMed Web of Science ®Google Scholar
• Canto EI , SinghH, ShariatSFet al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 (5), 905 – 910 (2004).
   PubMed Web of Science ®Google Scholar
• Mikolajczyk SD , MillarLS, WangTJet al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 60 (3), 756 – 759 (2000).
   PubMed Web of Science ®Google Scholar
• Peter J , UnverzagtC, KroghTN, VormO, HoeselW. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.Cancer Res.61 (3), 957 – 962 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar A , GoelAS, HillTMet al. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res. 56 (23), 5397 – 5402 (1996).
   PubMed Web of Science ®Google Scholar
• Isharwal S , MakarovDV, SokollLJet al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 77 (3), 763.e1 – 763.e6 (2011).
   PubMed Web of Science ®Google Scholar
• Tosoian JJ , LoebS, FengZet al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J. Urol. 188 (4), 1131 – 1136 (2012).
   PubMed Web of Science ®Google Scholar
• Vickers AJ , CroninAM, RoobolMJet al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin. Cancer Res. 16 (12), 3232 – 3239 (2010).
   PubMed Web of Science ®Google Scholar
• Lin DW , NewcombLF, BrownECet al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin. Cancer Res. 19 (9), 2442 – 2450 (2013).
   PubMed Web of Science ®Google Scholar
• Hoeks CM , SomfordDM, van OortIMet al. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a Prospective Multicenter Cohort Study. Invest. Radiol. 49 (3), 165 – 172 (2013).
   Web of Science ®Google Scholar
• Stamatakis L , SiddiquiMM, NixJWet al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 119 (18), 3359 – 3366 (2013).
   PubMed Web of Science ®Google Scholar